Longeveron (LGVN) Capital Expenditures (2020 - 2026)
Longeveron (LGVN) posted quarterly Capital Expenditures of $57000.0 for Q3 2025, down 86.74% year-over-year from $430000.0 in Q3 2024, and down 64.6% quarter-over-quarter from $161000.0 in Q2 2025.
Longeveron (LGVN) Capital Expenditures (2020 - 2026) Analysis & Trends
Longeveron's Capital Expenditures history runs 6 years deep, the most recent figure standing at $57000.0 for Q3 2025.
- In Q3 2025, Capital Expenditures fell 86.74% year-over-year to $57000.0; the TTM figure through Mar 2026 stood at $218000.0 (down 67.27% YoY), while the FY2025 annual figure was $245000.0, down 62.6% from the prior year.
- Capital Expenditures for Q3 2025 stood at $57000.0, down from $161000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $430000.0 in Q3 2024, with the low at $3000.0 in Q3 2023.
- The 5-year median for Capital Expenditures is $72000.0 (2022), against an average of $130125.0.
- The sharpest annual moves came in 2023 and 2024: Capital Expenditures plunged 99.21% in 2023, then soared 14233.33% in 2024.
- Longeveron's Capital Expenditures stood at $312000.0 in 2021, then tumbled by 78.85% to $66000.0 in 2022, then soared by 148.48% to $164000.0 in 2023, then sank by 92.07% to $13000.0 in 2024, then soared by 338.46% to $57000.0 in 2025.
- Business Quant data shows LGVN's Capital Expenditures at $57000.0 in Q3 2025, $161000.0 in Q2 2025, and $27000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | 103,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 103,000.00 |
| Jun 30, 2026 | 103,000.00 |
| Sep 30, 2025 | 57,000.00 |
| Sep 30, 2025 | 57,000.00 |
| Jun 30, 2025 | 161,000.00 |
| Jun 30, 2025 | 161,000.00 |
| Mar 31, 2025 | 27,000.00 |
| Mar 31, 2025 | 27,000.00 |
| Dec 31, 2024 | 13,000.00 |
| Dec 31, 2024 | 13,000.00 |
| Sep 30, 2024 | 430,000.00 |
| Sep 30, 2024 | 430,000.00 |
| Jun 30, 2024 | 196,000.00 |
| Jun 30, 2024 | 196,000.00 |
| Mar 31, 2024 | 16,000.00 |
| Mar 31, 2024 | 16,000.00 |
| Dec 31, 2023 | 164,000.00 |
| Dec 31, 2023 | 164,000.00 |
| Sep 30, 2023 | 3,000.00 |
| Sep 30, 2023 | 3,000.00 |